Table S2 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Authors:
- Andreas GollnerAGAndreas Gollner
- Dorothea RudolphDRDorothea Rudolph
- Ulrike Weyer-CzernilofskyUWUlrike Weyer-Czernilofsky
- Rosa BaumgartingerRBRosa Baumgartinger
- Peter JungPJPeter Jung
- Harald WeinstablHWHarald Weinstabl
- Jürgen RamharterJRJürgen Ramharter
- Rolf GremplerRGRolf Grempler
- Jens QuantJQJens Quant
- Jörg RinnenthalJRJörg Rinnenthal
- Alejandro Pérez PitarchAPAlejandro Pérez Pitarch
- Bojana GolubovicBGBojana Golubovic
Open Access
- 17 June 2026
- other
- Published by American Association for Cancer Research (AACR)